Negara: Inggris
Bahasa: Inggris
Sumber: MHRA (Medicines & Healthcare Products Regulatory Agency)
White soft paraffin; Cetostearyl alcohol; Macrogol cetostearyl ether 22; Liquid paraffin; Chlorocresol; Purified water
Formula A) (Thornton & Ross Ltd
n/a
White soft paraffin; Cetostearyl alcohol; Macrogol cetostearyl ether 22; Liquid paraffin; Chlorocresol; Purified water
150mg/1gram ; 72mg/1gram ; 18mg/1gram ; 60mg/1gram ; 1mg/1gram ; 699mg/1gram
Cutaneous cream
Cutaneous
No Controlled Drug Status
Valid as a prescribable product
BNF: 13010100; GTIN: 5011309140514
CETOMACROGOL CREAM BP 1988 FORMULA A Baca dokumen lengkapnya
OBJECT 1 CETOMACROGOL CREAM BP 1988 FORMULA A Summary of Product Characteristics Updated 03-Dec-2014 | Thornton & Ross Ltd 1. Name of the medicinal product Cetomacrogol Cream BP 1988 Formula A 2. Qualitative and quantitative composition Macrogol Cetostearyl Ether 22 1.8% w/w 3. Pharmaceutical form Cream. 4. Clinical particulars 4.1 Therapeutic indications For external application for use as an emollient, and for use as a diluent in medicinal external preparations. 4.2 Posology and method of administration Topical Recommended dose and dosage schedule To be used as prescribed by a registered medical practitioner or counter prescribed by a registered pharmacist. The product is suitable for use by adults, children and the elderly. Dosage: as prescribed by the medical practitioner or pharmacist. 4.3 Contraindications Sensitivity to chlorocresol. 4.4 Special warnings and precautions for use For external use only. Keep all medicines away from children. Store below 25°C. Do not allow to freeze. The diluted cream should be used within 2 weeks of preparation. 4.5 Interaction with other medicinal products and other forms of interaction None known. 4.6 Fertility, pregnancy and lactation No special precautions regarding this vehicle. 4.7 Effects on ability to drive and use machines None known. 4.8 Undesirable effects None known. REPORTING OF SUSPECTED ADVERSE REACTIONS Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard. 4.9 Overdose Not applicable. 5. Pharmacological properties 5.1 Pharmacodynamic properties The product has an emollient effect. 5.2 Pharmacokinetic properties Not applicable. 5.3 Preclinical safety data None. 6. Pharmaceutical particulars 6.1 List of excipients Cetostearyl Alcohol Chlorocresol Liquid Paraffin Paraffin White Soft Water Purified 6.2 I Baca dokumen lengkapnya